00:25 GMT28 November 2020
Listen Live
    World
    Get short URL
    by
    4153
    Subscribe

    Remdesivir is an antiviral medication developed by biopharmaceutical company Gilead Sciences. The drug is approved in some countries for the treatment of COVID-19. In October, Remdesivir became the first coronavirus treatment approved in the US by the Food and Drug Administration (FDA).

    On Thursday, the World Health Organization (WHO) advised doctors against using Remdesivir as a treatment for COVID-19 patients, saying that there is "no evidence" that the drug shortens recovery time.

    The recommendations were published by the WHO Guideline Development Group, which provides advice based on the most recent data, in the British medical trade journal The BMJ. 

    “After thoroughly reviewing this evidence, the WHO GDG expert panel, which includes experts from around the world including four patients who have had covid-19, concluded that remdesivir has no meaningful effect on mortality or on other important outcomes for patients, such as the need for mechanical ventilation or time to clinical improvement,” the group wrote in a press release.

    The WHO recommendations were based on results of four international drug trials involving over 7,000 patients infected with the coronavirus disease.

    In response, Gilead stated that the drug was recognized by some health institutes in the US, as well as several expert communities in Japan, the UK and Germany.

    “We are disappointed the WHO guidelines appear to ignore this evidence at a time when cases are dramatically increasing around the world and doctors are relying on Veklury as the first and only approved antiviral treatment for patients with COVID-19 in approximately 50 countries,” Gilead spokesman Chris Ridley said in a statement cited by CNBC.

    Under the brand name Veklury, the drug is administered intravenously, and is recommended to be used only in clinical settings comparable to hospital inpatient care.

    The FDA officially approved the use of remdesivir in October, making it the first approved COVID-19 treatment in the US. Gilead referred to this approval as a "milestone" that indicated a "shared commitment" to help speed the healing of those infected by the novel coronavirus.

    President Donald Trump removes his mask as he stands on the Blue Room Balcony upon returning to the White House Monday, Oct. 5, 2020, in Washington, after leaving Walter Reed National Military Medical Center, in Bethesda, Md. Trump announced he tested positive for COVID-19 on Oct. 2
    © AP Photo / Alex Brandon
    President Donald Trump removes his mask as he stands on the Blue Room Balcony upon returning to the White House Monday, Oct. 5, 2020, in Washington, after leaving Walter Reed National Military Medical Center, in Bethesda, Md. Trump announced he tested positive for COVID-19 on Oct. 2

    Remdesivir came to the attention of the public earlier this year after being reported to have reduced recovery times for some patients infected with COVID-19. According to one doctor who treated US President Donald Trump, when the latter became infected with the disease, he was given the drug to shorten the time of his recovery.

    The first vaccine against COVID-19, Sputnik V, registered in August in Russia and the world, is currently undergoing phase 3 trials in Russia, Belarus, Venezuela and the UAE. The vaccine is reported to have a 92-percent efficacy in preventing the infection, according to data from trial participants who have received both of the two vaccine injections.

    Related:

    EU in Talks With Gilead to Secure Remdesivir After US Bought Up Supply
    Indian Gov't Not Satisfied With Drugs Remdesivir, Favipiravir's Efficacy in COVID-19 Treatment
    Experimental Use of Antiviral Drug Remdesivir Shows COVID-19 Patients Recovering Quickly
    Trump: FDA Grants Emergency Authorization of Remdesivir to Treat COVID-19
    Cheaper Than Remdesivir: Russia to Supply Anti-COVID Avifavir to 17 Countries
    Remdesivir May Be Lifesaving for COVID-19 Patients, Yet Toxic for US-EU Relations
    EU Greenlights Use of Remdesivir to Treat COVID-19
    Gilead Plans to Charge Over $3,000 for COVID-19 Antiviral Remdesivir
    Tags:
    drug, vaccine, Sputnik V, Trump, Gilead Sciences, treatment, coronavirus, COVID-19, World Health Organization (WHO), US
    Community standardsDiscussion